Clario and Cleveland Clinic's Cole Eye Institute announce strategic partnership to provide new ophthalmology offerings for clinical trials.
Clario, a global clinical research organization (CRO), and Cleveland Clinic's Cole Eye Institute have joined forces in a strategic partnership. The collaboration aims to enhance ophthalmology offerings for clinical trials. By leveraging Clario's expertise in clinical research and Cleveland Clinic's renowned Cole Eye Institute's proficiency in ophthalmology and AI-driven analysis, the partnership seeks to advance research and development in eye-related treatments and therapies. This alliance holds promise for accelerating the pace of innovation in ophthalmic care, ultimately benefiting patients worldwide.
The Cole Eye Institute offers a seasoned team of graders who contribute their image assessment expertise to the Clario trial process, ensuring sponsors receive top-notch endpoint data, thus expediting the time to market for novel treatments. This support extends across various indications, including age-related macular degeneration, retinal vascular diseases, diabetic retinopathy, inherited retinal degenerations, as well as non-ophthalmic conditions like multiple sclerosis and Alzheimer's disease.
Clario's global team of science, technology, and operational experts have helped deliver over 26,000 trials and contributed to over 800 regulatory approvals in more than 100 countries.
Read the full press release via PRNewswire